Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

An Usefulness of In Vitro Interferon Gamma Assay for the Diagnosis of Latent Tuberculosis Infection in Middle- and High-School Students in Jeju-Shi, Korea

제주시 중고등학생의 잠복결핵감염 진단을 위한 체외 인터페론감마검사의 유용성

  • Bae, Jong-Myon (Department of Preventive Medicine, Jeju National University School of Medicine) ;
  • Kim, Eun-Hee (Department of Preventive Medicine, Jeju National University School of Medicine) ;
  • Wang, Ok-Bo (Jeju Public Health Center, Jeju Special Self-Governing Province)
  • 배종면 (제주대학교 의과대학 예방의학교실) ;
  • 김은희 (제주대학교 의과대학 예방의학교실) ;
  • 왕옥보 (제주보건소)
  • Received : 2010.01.25
  • Accepted : 2010.02.17
  • Published : 2010.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The tuberculin skin test (TST) has limitations in diagnosing a latent tuberculosis infection (LTBI). The interferon-gamma release assay (IGRA) was introduced to middle- and high-school students since 2009 by the Korea Centers for Disease Control and Prevention. The aim was to evaluate the utility of IGRA in diagnosing LTBI in middle- and high-school students. Methods: From August 2007 to July 2009, among suspected LTBI students showing TST induration with a 10 mm diameter and over with a normal chest x-ray in school students of Jeju city, 341 students underwent a Quanti FERON-TB Gold In-Tube (QFT-IT) test to confirm LTBI. Results: From 348 students showing a positive TST, a QFT-IT test was carried out on 341 students. The positive QFT-IT rate was 52.8% (=180/341). The positive QFT-IT rate was higher in high-school boys with a 15~19 mm diameter of induration in TST. Conclusion: With the introduction of IGRA for diagnosing LTBI in middle- and high-school students, approximately 47% of students who show a TST induration with a 10 mm diameter and over can avoid taking unnecessary preventive chemotherapy. These results suggest that IGRA is useful for diagnosing and controlling LTBI in Korean students.

Keywords

References

  1. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing. Global report 2009 [Internet]. Geneva: World Health Organization; 2009 [cited 2010 Feb 15]. Available from: http://www.who.int/tb/publications/global_report/2009/en/index.html.
  2. Korea Centers for Diseases Control and Prevention. Tuberculosis [Internet]. Seoul: Korea Centers for Diseases Control and Prevention; 2010 [cited 2010 Feb 15]. Available from: http://tbfree.cdc.go.kr.
  3. Shim TS, Koh WJ, Yim JJ, Lew WJ. Diagnosis and treatment of latent tuberculosis infection in Korea. Tuberc Respir Dis 2004;57:101-8. https://doi.org/10.4046/trd.2004.57.2.101
  4. Swindells JE, Aliyu SH, Enoch DA, Abubakar I. Role of interferon-gamma release assays in healthcare workers. J Hosp Infect 2009;73:101-8. https://doi.org/10.1016/j.jhin.2009.05.005
  5. Lee JY, Shim TS. Diagnosis of Mycobacterium tuberculosis infection using ex-vivo interferon-gamma assay. Tuberc Respir Dis 2006;60:497-509. https://doi.org/10.4046/trd.2006.60.5.497
  6. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn 2006;6:413-22. https://doi.org/10.1586/14737159.6.3.413
  7. Madariaga MG, Jalali Z, Swindells S. Clinical utility of interferon gamma assay in the diagnosis of tuberculosis. J Am Board Fam Med 2007;20:540-7.
  8. Pai M, Gokhale K, Joshi R, Dogra S, Kalantri S, Mendiratta DK, et al. Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood interferon gamma assay with tuberculin skin testing. JAMA 2005;293:2746-55. https://doi.org/10.1001/jama.293.22.2746
  9. Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004;4:761-76. https://doi.org/10.1016/S1473-3099(04)01206-X
  10. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45. https://doi.org/10.1016/S0140-6736(95)92348-9
  11. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004;170:65-9. https://doi.org/10.1164/rccm.200402-232OC
  12. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340-54. https://doi.org/10.7326/0003-4819-146-5-200703060-00006
  13. Shalabi NM, Houssen ME. Discrepancy between the tuberculin skin test and the levels of serum interferongamma in the diagnosis of tubercular infection in contacts. Clin Biochem 2009;42:1596-601. https://doi.org/10.1016/j.clinbiochem.2009.08.013
  14. Machado A Jr, Emodi K, Takenami I, Finkmoore BC, Barbosa T, Carvalho J, et al. Analysis of discordance between the tuberculin skin test and the interferongamma release assay. Int J Tuberc Lung Dis 2009;13:446-53.
  15. Tsara V, Serasli E, Christaki P. Problems in diagnosis and treatment of tuberculosis infection. Hippokratia 2009;13:20-2.
  16. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000;356:1099-104. https://doi.org/10.1016/S0140-6736(00)02742-2
  17. Lalvani A. Spotting latent infection: the path to better tuberculosis control. Thorax 2003;58:916-8. https://doi.org/10.1136/thorax.58.11.916
  18. Cellestis. QuantiFERON technology [Internet]. Valencia:Cellestis Inc.; 2010 [cited 2010 Feb 15]. Available from: http:// www.cellestis.com.
  19. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282:677-86. https://doi.org/10.1001/jama.282.7.677
  20. Styblo K. Recent advances in epidemiological research in tuberculosis. Adv Tuberc Res 1980;20:1-63.
  21. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993;17:968-75. https://doi.org/10.1093/clinids/17.6.968
  22. Reid JK, Ward H, Marciniuk D, Hudson S, Smith P, Hoeppner V. The effect of neonatal bacille Calmette-Guerin vaccination on purified protein derivative skin test results in Canadian aboriginal children. Chest 2007;131:1806-10. https://doi.org/10.1378/chest.06-1133
  23. Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2006;174:736-42. https://doi.org/10.1164/rccm.200509-1516PP
  24. Eum SY, Lee YJ, Kwak HK, Min JH, Hwang SH, Via LE, et al. Evaluation of the diagnostic utility of a wholeblood interferon-gamma assay for determining the risk of exposure to Mycobacterium tuberculosis in Bacille Calmette-Guerin (BCG)-vaccinated individuals. Diagn Microbiol Infect Dis 2008;61:181-6. https://doi.org/10.1016/j.diagmicrobio.2008.01.002
  25. Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G, et al. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001;167:5217-25. https://doi.org/10.4049/jimmunol.167.9.5217
  26. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177-84. https://doi.org/10.7326/0003-4819-149-3-200808050-00241
  27. Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005;293:2756-61. https://doi.org/10.1001/jama.293.22.2756
  28. Dheda K, Udwadia ZF, Huggett JF, Johnson MA, Rook GA. Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis. Curr Opin Pulm Med 2005;11:195-202. https://doi.org/10.1097/01.mcp.0000158726.13159.5e
  29. Lee JY, Choi HJ, Park IN, Hong SB, Oh YM, Lim CM, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006;28:24-30. https://doi.org/10.1183/09031936.06.00016906
  30. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the Quanti FERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005;54:49-55.
  31. Canadian Tuberculosis Committee. Interferon gamma release assays for latent tuberculosis infection: an Advisory Committee Statement (ACS). Can Commun Dis Rep 2007;33:1-18.
  32. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004;170:59-64. https://doi.org/10.1164/rccm.200402-179OC
  33. Nienhaus A, Schablon A, Bacle CL, Siano B, Diel R. Evaluation of the interferon-gamma release assay in healthcare workers. Int Arch Occup Environ Health 2008;81:295-300.
  34. Harada N, Nakajima Y, Higuchi K, Sekiya Y, Rothel J, Mori T. Screening for tuberculosis infection using whole-blood interferon-gamma and Mantoux testing among Japanese healthcare workers. Infect Control Hosp Epidemiol 2006;27:442-8. https://doi.org/10.1086/504358
  35. Lalvani A, Pathan AA, McShane H, Wilkinson RJ, Latif M, Conlon CP, et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen- specific T cells. Am J Respir Crit Care Med 2001;163:824-8. https://doi.org/10.1164/ajrccm.163.4.2009100
  36. Fietta A, Meloni F, Cascina A, Morosini M, Marena C, Troupioti P, et al. Comparison of a whole-blood interferon-gamma assay and tuberculin skin testing in patients with active tuberculosis and individuals at high or low risk of Mycobacterium tuberculosis infection. Am J Infect Control 2003;31:347-53. https://doi.org/10.1016/S0196-6553(02)48240-5
  37. Choi JC, Shin JW, Kim JY, Park IW, Choi BW, Lee MK. The effect of previous tuberculin skin test on the follow-up examination of whole-blood interferon-gamma assay in the screening for latent tuberculosis infection. Chest 2008;133:1415-20. https://doi.org/10.1378/chest.07-2193
  38. Hotta K, Ogura T, Nishii K, Kodani T, Onishi M, Shimizu Y, et al. Whole blood interferon-gamma assay for baseline tuberculosis screening among Japanese healthcare students. PLoS One 2007;2:e803. https://doi.org/10.1371/journal.pone.0000803
  39. Lee JY, Choi HJ, Cho SN, Park IN, Oh YM, Lee SD, et al. Effect of tuberculin skin test on ex-vivo interferon-gamma assay for latent tuberculosis infection. Tuberc Respir Dis 2005;59:406-12. https://doi.org/10.4046/trd.2005.59.4.406
  40. Richeldi L, Ewer K, Losi M, Bergamini BM, Roversi P, Deeks J, et al. T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. Am J Respir Crit Care Med 2004;170:288-95. https://doi.org/10.1164/rccm.200403-307OC

Cited by

  1. 폐결핵환자 접촉자에서 결핵감염의 빈도와 결핵감염의 위험인자 vol.72, pp.2, 2010, https://doi.org/10.4046/trd.2012.72.2.140
  2. 우리나라 잠복결핵감염 검진전략의 경제성 분석 vol.23, pp.4, 2013, https://doi.org/10.4332/kjhpa.2013.23.4.349